Oncology - European Medical Journal

Continue

Oncology

Filter
EMJ Oncology 10 [Supplement 6] 2022 Feature Image
13 Mins
21 Mar 2022

Multidisciplinary Team Approach in Cancer Care: A Review of the Latest Advancements Featured at ESMO 2021

A collaborative approach from healthcare professionals is necessary for the management of patients with cancer to diagnose and treat…
EMJ Oncology 10 [Supplement 5] 2022 Feature Image
8 Mins
7 Mar 2022

Implementation of MET Molecular Testing in the Clinic: Latest Evidence for Mesenchymal–Epithelial Transition Inhibitors in Non-small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a heterogeneous disease with many genomic mutations. Furthermore, comprehensive genomic…
EMJ Oncology 10 [Supplement 4] 2022 Feature Image
7 Mins
24 Feb 2022

Evolving the Role for Immunotherapy in Lung Cancer: Extensive-Stage Small Cell Lung Cancer and Unresectable Stage III Non-small Cell Lung Cancer

Lung cancer is classified into NSCLC (85% of patients) and SCLC (15%). NSCLC can be further classified histologically into three main type…
11 Mins
18 Feb 2022

New Developments, Data, and Guideline Updates: Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism Associated with Cancer – Interviews with Key Opinion Leaders

CAT is a serious complication that can affect up to 6% of patients with cancer, and is associated with a 2–5-fold increased risk of…
EMJ Oncology 10 [Supplement 2] 2022 feature
14 Mins
3 Feb 2022

Optimising Cholangiocarcinoma Diagnosis and Treatment Focusing on Precision Medicine

This article is based on interviews conducted with Lorenza Rimassa, Arndt Vogel, and Harpreet Wasan. They provided their expert opinion…
10 Mins
21 Jan 2022

Increasing Therapy Options in Solid Tumours: A Consideration of Testing Methodologies in Non-small Cell Lung Cancer and Breast Cancer

Lung cancer has a devastating global impact, claiming almost 2 million lives in 2020.1 Despite advances in treatment, lung cancer remains the world’s leading cause of cancer-related morbidity and mortality.
6 Mins
9 Dec 2021

Neurofibromatosis Type 1: Burden of Disease in Patients with Plexiform Neurofibromas

NF1 is an autosomal dominant disorder, arising from a mutation in the gene that encodes neurofibromin. It is a tumour-predisposing…
6 Mins
9 Dec 2021

Management and Multi-specialty Approach in the Evolving Treatment Landscape of Neurofibromatosis Type 1 Plexiform Neurofibromas

Neurofibromatosis Type 1 (NF1) is a rare disease, occurring in approximately 1 in 3,000 people. Among the numerous manifestations…
We’ve noticed you’re accessing
from North/South America.